Table 2.

The role of HLA-DQ heterodimers in HLA-matched unrelated-donor transplantation

Feature*	Population	Clinical endpoint	Genotype	Patients, n	Hazard ratio (95% CI; P value)†
HLA-DQ group genotype	HLA-matched patients	Relapse	G1G1	1597	1.0
			G1G2	2434	1.20 (1.08-1.34; .0009)
			G2G2	848	1.22 (1.06-1.40; .006)
		Disease-free survival	G1G1	1688	1.0
			G1G2	2566	1.08 (1.01-1.17; .03)
			G2G2	897	1.11 (1.00-1.22; .04)
Dose effect of number of G1 molecules	HLA-matched patients	Relapse	No G1	848	1.0
			One G1	2702	0.97 (0.85-1.10; .65)
			Two G1	495	0.82 (0.68-0.99; .04)
			Four G1	834	0.85 (0.72-1.00; .05)
		Disease-free survival	No G1	897	1.0
			One G1	2858	0.96 (0.88-1.05; .38)
			Two G1	519	0.89 (0.78-1.01; .07)
			Four G1	877	0.93 (0.83-1.04; .20)
Dose effect of number of G2 molecules	HLA-matched patients	Relapse	No G2	1597	1.0
			One G2	2661	1.19 (1.07-1.33; .001)
			Two G2	107	1.53 (1.13-2.08; .006)
			Four G2	514	1.25 (1.06-1.48; .008)
		Disease-free survival	No G2	1688	1.0
			One G2	2806	1.07 (1.00-1.15; .06)
			Two G2	115	1.24 (0.99-1.54; .06)
			Four G2	542	1.12 (1.00-1.26; .05)

n = 5164.

^*The most frequently observed G2 molecule in patients bearing G1G2 and G2G2 was DQA1*01:02P-DQB1*06:02P (0.38 haplotype frequency); those with G1G1 most frequently encoded DQA1*05:01P-DQB1*02:01P (28.8%).

^†Models adjusted for preparative regimen, diagnosis, cytomegalovirus serostatus, patient age, donor age, stem cell source, patient sex, donor sex, use of total body irradiation, use of T-cell depletion, presence of DPB1 mismatch, and year of transplantation (genotype model).